Retour au classement

Merit Medical Systems, Inc. (MMSI)

NEUTRAL
HealthcareMedical Instruments & SuppliesUnited States

Fondamental

72

Prix

$91.70

Capitalisation boursière

$5.42B

Partie 1 · Ce que vaut l'entreprise

Vue d'ensemble

Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States, China, Japan, Germany, France, the United Kingdom, and internationally. It operates through two segments, Cardiovascular and Endoscopy. The company offers micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention products comprising angiography, drainage, delivery systems, and embolotherapy products; oncology products, such as soft tissue biopsy products and accessories; cardiac intervention products consisting of cardiac access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention products; and spine products, including vertebral augmentation, radiofrequency ablation, and bone biopsy systems. It also provides custom procedural solutions, including critical care products, syringes, manifold kits, and trays and packs; coating services for medical tubes and wires; and sensor components for microelectromechanical systems. In addition, the company offers gastroenterology products, such as esophageal stents, cryoballoon and inflation devices, gauges, and balloon dilators; pulmonary products consisting of laser-cut tracheobronchial stents, and over-the-wire and direct visualization delivery systems; and kits and accessories for endoscopy and bronchoscopy procedures. It sells its products to hospitals, alternate site-based physicians, technicians, and nurses through direct sales force, independent distributors, original equipment manufacturer partners, and custom procedure tray manufacturers. The company exports its products to Canada, Western Europe, Australia, Brazil, Malaysia, South Korea, the United Arab Emirates, India, New Zealand, and South Africa. Merit Medical Systems, Inc. was incorporated in 1987 and is headquartered in South Jordan, Utah.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

Bilan & Liquidités

Chiffre d'affaires

$1.58B

12 derniers mois (au 30/06/2026)

Résultat net

$146M

12 derniers mois (au 30/06/2026)

Flux de trésorerie libre

$216M

Capitaux propres totaux

$1.58B

Passif total

$1.10B

Ratio de liquidité général

4.20

Couverture des intérêts

6.34

Dette/EBITDA

2.66

Bénéfice par action

Chiffre d'affaires & Résultat net

Flux de trésorerie libre

Décomposition du résultat

État historique

Marges dans le temps

La dette dans le temps

Le poids de la dette

Grille de la croissance

Croissance — Chiffre d'affaires

Estimation de la juste valeur

General caseSurévalué

Juste valeur

$74.50

Prix actuel

$91.70

Marge de sécurité

-23.1%

Fourchette de juste valeur

$48.43 - $100.58

Méthodes d'estimation

Analyst price target:$100.27
Discounted cash flow (DCF):$92.48
Earnings multiple (P/E):$47.60
Graham growth formula:$39.56
Earnings power value (EPV):$33.13
Justified P/B:$31.85
Dividend discount (Gordon):Not enough data to compute it
P/FFO, funds from operations:Not enough data to compute it
Mid-cycle earnings:$39.47
Revenue multiple:Not enough data to compute it
Consensus des analystes:Achat fort (14B / 3H / 0S)
Dernière surprise sur les résultats:+21.65%

Indicateurs de valorisation

Ratio P/E

37.15

ROE

8.1%

Ratio P/B

3.21

P/FCF

26.53

Marge brute

49.5%

ROIC

6.1%

Radar de rentabilité

Value Creation (Economic Moat)

ROIC

6.1%

WACC

7.3%

ROIC − WACC

-1.2 pp

ROIC is below the cost of capital — the company is destroying value for every dollar invested.

Critères d'analyse fondamentale

Réussi (21)

  • EPS shows upward trend
  • EPS CAGR 7.91%
  • Price CAGR 13.10%
  • ROIC 6.1%
  • Gross Margin 49.5%
  • P/FCF 26.53
  • Debt/Equity ratio
  • Operating Margin 12.8%
  • Positive Free Cash Flow
  • Current Ratio
  • Interest Coverage
  • Debt/EBITDA
  • Return on Tangible Assets
  • ROE 9.1%
  • Revenue Growth 5Y 9.5%
  • Analyst Consensus 82% Buy
  • Earnings Surprise avg 11.9%
  • Earnings Quality (OCF/NI) 1.95
  • Share Dilution 1.7%
  • Net Margin Trend 9.2% vs 8.3%
  • Piotroski F-Score 7/9

Échoué (5)

  • P/B Ratio 3.21
  • CapEx intensity
  • Low reliance on intangibles
  • Price below Graham Number
  • DCF valuation (Overvalued)

Indisponible (2)

  • Dividend Payout NaN%
  • PEG Ratio (need PE > 0 and growth > 0)

Score F de Piotroski

7/9

Santé financière solide

score
criteria

Qualité des bénéfices

1.95

Qualité élevée : bénéfices soutenus par la trésorerie

Dilution du capital

1.7%

Le nombre d'actions est stable

Gouvernance

Équipe dirigeante

NomTitreÂge
Ms. Martha Goldberg AronsonPresident, CEO & Director58
Mr. Raul Parra Jr., CPACFO & Treasurer46
Mr. Brian G. Lloyd J.D.Chief Legal Officer & Corporate Secretary64
Mr. Michel J. VoigtChief Human Resources Officer52
Mr. Jason TreftChief Information Officer-
Ms. Sarah ComstockVice President of Global Communications-
Mr. John KnorppChief Regulatory Affairs Officer-
Mr. Ricardo AlvarezManaging Director of Operation Merit Medical Tijuana-
Mr. Mark ButlerExecutive Vice President of Merit Medical EMEA-
Ms. Alisha JerauldSustainability Council Chair and Vice President of Environment, Social & Governance-

Risque d'audit

2

Risque du conseil

2

Risque de rémunération

1

Risque droits des actionnaires

4

Partie 2 · Le prix et le moment d'entrer

Cette partie ne dit pas si l'entreprise vaut la peine : elle aide à choisir quand l'acheter, une fois que les fondamentaux vous ont convaincu. À l'intérieur : analyse technique, potentiel, baisses historiques, exposition gamma.

Latest News

Recent headlines for MMSI, sourced from Markets Gazette.

No recent news for MMSI.